Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges.

Autor:	Razeghian E; Human Genetics Division, Medical Biotechnology Department, National Institute of Genetics Engineering and Biotechnology (NIGEB), Tehran, Iran., Suksatan W; Faculty of Nursing, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand., Sulaiman Rahman H; Department of Physiology, College of Medicine, University of Suleimanyah, Suleimanyah, Iraq.; Department of Medical Laboratory Sciences, Komar University of Science and Technology, Sulaimaniyah, Iraq., Bokov DO; Institute of Pharmacy, Sechenov First Moscow State Medical University, Moscow, Russia.; Laboratory of Food Chemistry, Federal Research Center of Nutrition, Biotechnology and Food Safety, Moscow, Russia., Abdelbasset WK; Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia.; Department of Physical Therapy, Kasr Al-Aini Hospital, Cairo University, Giza, Egypt., Hassanzadeh A; Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran., Marofi F; Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, Iran., Yazdanifar M; Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, United States., Jarahian M; Toxicology and Chemotherapy Unit (G401), German Cancer Research Center, Heidelberg, Germany.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2021 Aug 20; Vol. 12, pp. 699746. Date of Electronic Publication: 2021 Aug 20 (Print Publication: 2021).
DOI:	10.3389/fimmu.2021.699746
Abstrakt:	The immune cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has attracted rapidly evolving attention as a cancer treatment modality because of its competence to selectively eliminate tumor cells without instigating toxicity in vivo . TRAIL has revealed encouraging promise in preclinical reports in animal models as a cancer treatment option; however, the foremost constraint of the TRAIL therapy is the advancement of TRAIL resistance through a myriad of mechanisms in tumor cells. Investigations have documented that improvement of the expression of anti-apoptotic proteins and survival or proliferation involved signaling pathways concurrently suppressing the expression of pro-apoptotic proteins along with down-regulation of expression of TRAILR1 and TRAILR2, also known as death receptor 4 and 5 (DR4/5) are reliable for tumor cells resistance to TRAIL. Therefore, it seems that the development of a therapeutic approach for overcoming TRAIL resistance is of paramount importance. Studies currently have shown that combined treatment with anti-tumor agents, ranging from synthetic agents to natural products, and TRAIL could result in induction of apoptosis in TRAIL-resistant cells. Also, human mesenchymal stem/stromal cells (MSCs) engineered to generate and deliver TRAIL can provide both targeted and continued delivery of this apoptosis-inducing cytokine. Similarly, nanoparticle (NPs)-based TRAIL delivery offers novel platforms to defeat barricades to TRAIL therapeutic delivery. In the current review, we will focus on underlying mechanisms contributed to inducing resistance to TRAIL in tumor cells, and also discuss recent findings concerning the therapeutic efficacy of combined treatment of TRAIL with other antitumor compounds, and also TRAIL-delivery using human MSCs and NPs to overcome tumor cells resistance to TRAIL. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Razeghian, Suksatan, Sulaiman Rahman, Bokov, Abdelbasset, Hassanzadeh, Marofi, Yazdanifar and Jarahian.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu